PLUS1
Best deals to access real time data! |
|
Ultimate Trader (Monthly)
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Big Cap Pro
Monthly Subscription
for only
|
|
VAT not included
|
|
After Hours Last Trade |
Last $ 305.02 ◊ 0.00 (0.00%) | |
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Regeneron Pharmaceuticals Inc | REGN | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | High Price | Low Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| 3.71 | 1.23% | 305.02 | 307.07 | 299.4701 | 301.86 | 301.31 | 20:00:00 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 286.00 | 318.00 | 32.00 | 10.06% | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 10,236 | 596,803 | $ 304.15 | $ 181,520,235 | 735,693 | 271.37 - 445.00 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 18:19:00 | 3 | $ 307.99 | USD |
Regeneron Pharmaceuticals Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 33.50B | 109.83M | $ 2.44B | 21.30 | 15.20 | 108.67M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | 1.10% |
Regeneron Pharmaceuticals News
| Date | Time | Source | News Article |
|---|---|---|---|
| 10/18/2019 | 08:30 | PR Newswire (US) | Regeneron Announces Upcoming Investor Conference.. |
| 10/10/2019 | 09:30 | PR Newswire (US) | Regeneron to Report Third Quarter 2019 Financial and.. |
| 10/08/2019 | 14:00 | Edgar (US Regulatory) | Confidential Treatment Order (ct Order) |
| 9/20/2019 | 07:22 | Dow Jones News | Regeneron, Sanofi Get Positive CHMP Opinion for Dupixent |
| 9/20/2019 | 06:59 | PR Newswire (US) | The Lancet Publishes Results from Two Positive Phase 3.. |
| 9/20/2019 | 06:44 | PR Newswire (US) | CHMP Recommends Approval of Dupixent® (dupilumab) for Severe.. |
| 9/18/2019 | 06:59 | PR Newswire (US) | Educational Campaign Helps Teens and Their Caregivers Tackle.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical REGN Price Data
| Period †| Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 301.62 | 307.07 | 294.86 | 300.08 | 601,863 | 3.40 | 1.13% |
| 1 Month | 290.21 | 310.15 | 271.37 | 291.19 | 701,450 | 14.81 | 5.1% |
| 3 Months | 309.80 | 313.93 | 271.37 | 292.32 | 671,240 | -4.78 | -1.54% |
| 6 Months | 335.51 | 351.90 | 271.37 | 304.39 | 749,100 | -30.49 | -9.09% |
| 1 Year | 384.17 | 445.00 | 271.37 | 343.13 | 746,225 | -79.15 | -20.6% |
| 3 Years | 364.51 | 543.5518 | 271.37 | 374.55 | 811,554 | -59.49 | -16.32% |
| 5 Years | 387.00 | 605.9299 | 271.37 | 401.66 | 793,314 | -81.98 | -21.18% |
Regeneron Pharmaceuticals Description
| Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has six marketed products: Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Zaltrap in colorectal cancer; Dupixent in atopic dermatitis and asthma; Libtayo in cutaneous squamous cell carcinoma; Arcalyst in CAPS; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal antibodies with Sanofi in immunology and cancer. |
